Sign in to view content

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2018

Related

Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study
David S. Boyer, MD
Updates from the Field
2021
Autologous Retinal Transplant for Macular Holes: Initial Experience
Tamer H. Mahmoud, MD, PhD
Updates from the Field
2017
Defining and Addressing Wet AMD Non-responders
Rishi P. Singh, MD
Updates from the Field
2019

Category: Age-Related Macular Degeneration

See more